Li et al. demonstrated that lovastatin markedly downregulated the paclitaxel-induced expression of programmed death-ligand 1 and increased the activity of CD8+ T cells, thus supporting paclitaxel-mediated inhibition of tumor growth [33]. Here, CD8A is linked to neoplasm.